Research Article
A Novel-Defined Necroptosis-Related miRNA Signature for Forecasting the Prognosis of Low-Grade Glioma
Table 2
Modified Fisher test of hsa-miR-148a-3p and clinical parameters.
| | Characteristic | Low expression of hsa-miR-148a-3p | High expression of hsa-miR-148a-3p | |
| | 264 | 265 | | | WHO grade, (%) | | | 0.629 | | G2 | 111 (23.8%) | 110 (23.6%) | | | G3 | 117 (25.1%) | 129 (27.6%) | | | IDH status, (%) | | | <0.001 | | WT | 5 (1%) | 92 (17.5%) | | | Mut | 257 (48.9%) | 172 (32.7%) | | | 1p/19q codeletion, (%) | | | <0.001 | | Codel | 114 (21.6%) | 58 (11%) | | | Noncodel | 150 (28.4%) | 207 (39.1%) | | | Primary therapy outcome, (%) | | | 0.012 | | PD | 42 (9.2%) | 68 (14.8%) | | | SD | 80 (17.4%) | 68 (14.8%) | | | PR | 37 (8.1%) | 26 (5.7%) | | | CR | 78 (17%) | 60 (13.1%) | | | Gender, (%) | | | 0.405 | | Female | 115 (21.7%) | 126 (23.8%) | | | Male | 149 (28.2%) | 139 (26.3%) | | | Race, (%) | | | 0.369 | | Asian | 6 (1.2%) | 2 (0.4%) | | | Black or African American | 10 (1.9%) | 12 (2.3%) | | | White | 242 (46.7%) | 246 (47.5%) | | | Age, (%) | | | 0.828 | | ≤40 | 130 (24.6%) | 134 (25.3%) | | | >40 | 134 (25.3%) | 131 (24.8%) | | | Histological type, (%) | | | 0.014 | | Astrocytoma | 83 (15.7%) | 113 (21.4%) | | | Oligoastrocytoma | 67 (12.7%) | 66 (12.5%) | | | Oligodendroglioma | 114 (21.6%) | 86 (16.3%) | | | Laterality, (%) | | | 0.392 | | Left | 135 (25.8%) | 122 (23.3%) | | | Midline | 3 (0.6%) | 4 (0.8%) | | | Right | 122 (23.3%) | 138 (26.3%) | | | OS event, (%) | | | <0.001 | | Alive | 217 (41%) | 177 (33.5%) | | | Dead | 47 (8.9%) | 88 (16.6%) | | | DSS event, (%) | | | <0.001 | | Alive | 220 (42.2%) | 179 (34.4%) | | | Dead | 41 (7.9%) | 81 (15.5%) | | | PFI event, (%) | | | 0.003 | | Alive | 177 (33.5%) | 143 (27%) | | | Dead | 87 (16.4%) | 122 (23.1%) | |
|
|
Annotation: DSS: disease-specific survival; PFI: disease-free interval.
|
